Company intelligence / Profile preview
Tisento Therapeutics
Cambridge, Massachusetts, United Statestisentotx.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Zagociguat showed excellent safety profile, exposure in the central nervous system, evidence of improvements in mitochondrial and neuronal function, and increased blood flow in the brain in a Phase 2a study. Currently conducting PRIZM Phase 2b study evaluating zagociguat for MELAS treatment[1][5].
- Therapeutic areas
- Rare Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Collaborations with leading clinicians at mitochondrial disease centers of excellence worldwide[2]
Beyond the preview
Go deeper on Tisento Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tisento Therapeutics.